Skip to main content
Top
Published in: Arthritis Research & Therapy 2/2003

01-09-2003 | Meeting abstract

TNF and anti-TNF agents in Behçet's disease

Author: KT Calamia

Published in: Arthritis Research & Therapy | Special Issue 2/2003

Login to get access

Excerpt

The rapid response and effectiveness of anti-TNF agents in the treatment of many immune mediated inflammatory disorders draws comparison to the response of rheumatoid arthritis to cortisone, first witnessed over 50 years ago by Philip Hench and colleagues at the Mayo Clinic. It is now known that many of the anti-inflammatory effects of corticosteroids are due to their inhibition of TNF production. A new dimension of efficacy is possible with TNF agents, however, in that inhibition of disease progression is now possible. Might these agents be considered the corticosteroids of the new millennium? Like rheumatoid arthritis and Crohn's disease, Behçet's disease is believed to be associated with a Th1-mediated immune response. Increased levels of TNF-α are found in Behçet's disease and has provided support for the empiric use of anti-TNF-α therapies used in a number of published cases and small case series. …
Metadata
Title
TNF and anti-TNF agents in Behçet's disease
Author
KT Calamia
Publication date
01-09-2003
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 2/2003
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar981

Other articles of this Special Issue 2/2003

Arthritis Research & Therapy 2/2003 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine